These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35140559)

  • 1. A randomized, double-blind, placebo-controlled trial to evaluate the hypoglycemic efficacy of the mcIRBP-19-containing
    Yang YS; Wu NY; Kornelius E; Huang CN; Yang NC
    Food Nutr Res; 2022; 66():. PubMed ID: 35140559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastro-Resistant Insulin Receptor-Binding Peptide from Momordica charantia Improved the Glucose Tolerance in Streptozotocin-Induced Diabetic Mice via Insulin Receptor Signaling Pathway.
    Lo HY; Li CC; Chen FY; Chen JC; Hsiang CY; Ho TY
    J Agric Food Chem; 2017 Oct; 65(42):9266-9274. PubMed ID: 28994284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus.
    Kim SK; Jung J; Jung JH; Yoon N; Kang SS; Roh GS; Hahm JR
    Complement Ther Med; 2020 Aug; 52():102524. PubMed ID: 32951763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel anti-inflammatory activity of mcIRBP from
    Liao PY; Lo HY; Liu IC; Lo LC; Hsiang CY; Ho TY
    Food Funct; 2022 Feb; 13(3):1268-1279. PubMed ID: 35023522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A gastro-resistant peptide from
    Liao PY; Lo HY; Liu IC; Lo LC; Hsiang CY; Ho TY
    Food Funct; 2022 Feb; 13(4):1822-1833. PubMed ID: 35083999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel insulin receptor-binding protein from Momordica charantia enhances glucose uptake and glucose clearance in vitro and in vivo through triggering insulin receptor signaling pathway.
    Lo HY; Ho TY; Li CC; Chen JC; Liu JJ; Hsiang CY
    J Agric Food Chem; 2014 Sep; 62(36):8952-61. PubMed ID: 25144709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bitter gourd reduces elevated fasting plasma glucose levels in an intervention study among prediabetics in Tanzania.
    Krawinkel MB; Ludwig C; Swai ME; Yang RY; Chun KP; Habicht SD
    J Ethnopharmacol; 2018 Apr; 216():1-7. PubMed ID: 29339109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the antidiabetic activities of Momordica charantia fruit juice in streptozotocin-induced diabetic rats.
    Mahmoud MF; El Ashry FE; El Maraghy NN; Fahmy A
    Pharm Biol; 2017 Dec; 55(1):758-765. PubMed ID: 28064559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Momordica charantia and type 2 diabetes: from in vitro to human studies.
    Habicht SD; Ludwig C; Yang RY; Krawinkel MB
    Curr Diabetes Rev; 2014 Jan; 10(1):48-60. PubMed ID: 24295371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bitter melon (Momordica charantia): a review of efficacy and safety.
    Basch E; Gabardi S; Ulbricht C
    Am J Health Syst Pharm; 2003 Feb; 60(4):356-9. PubMed ID: 12625217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the bioactive and consensus peptide motif from Momordica charantia insulin receptor-binding protein.
    Lo HY; Li CC; Ho TY; Hsiang CY
    Food Chem; 2016 Aug; 204():298-305. PubMed ID: 26988505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mcIRBP-19 of Bitter Melon Peptide Effectively Regulates Diabetes Mellitus (DM) Patients' Blood Sugar Levels.
    Hsu PK; Pan FFC; Hsieh CS
    Nutrients; 2020 Apr; 12(5):. PubMed ID: 32354072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bitter gourd (Momordica Charantia): A dietary approach to hyperglycemia.
    Krawinkel MB; Keding GB
    Nutr Rev; 2006 Jul; 64(7 Pt 1):331-7. PubMed ID: 16910221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoglycemic and hypolipidemic effects of different parts and formulations of bitter gourd (Momordica Charantia).
    Mahwish ; Saeed F; Arshad MS; Nisa MU; Nadeem MT; Arshad MU
    Lipids Health Dis; 2017 Nov; 16(1):211. PubMed ID: 29126447
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Çiçek SS
    Front Pharmacol; 2022; 13():904643. PubMed ID: 35656300
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro and in vivo α-amylase and α-glucosidase inhibiting activities of the protein extracts from two varieties of bitter gourd (Momordica charantia L.).
    Poovitha S; Parani M
    BMC Complement Altern Med; 2016 Jul; 16 Suppl 1(Suppl 1):185. PubMed ID: 27454418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bitter gourd (Momordica charantia) on glycaemic status in streptozotocin induced diabetic rats.
    Shetty AK; Kumar GS; Sambaiah K; Salimath PV
    Plant Foods Hum Nutr; 2005 Sep; 60(3):109-12. PubMed ID: 16187012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: A single-blinded, randomized controlled trial.
    Soo May L; Sanip Z; Ahmed Shokri A; Abdul Kadir A; Md Lazin MR
    Complement Ther Clin Pract; 2018 Aug; 32():181-186. PubMed ID: 30057048
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Bortolotti M; Mercatelli D; Polito L
    Front Pharmacol; 2019; 10():486. PubMed ID: 31139079
    [No Abstract]   [Full Text] [Related]  

  • 20. Antihyperglycemic effects of three extracts from Momordica charantia.
    Virdi J; Sivakami S; Shahani S; Suthar AC; Banavalikar MM; Biyani MK
    J Ethnopharmacol; 2003 Sep; 88(1):107-11. PubMed ID: 12902059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.